Lunai Bioworks Inc.LNAIEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Lunai Bioworks Inc. is a synthetic biology technology firm specializing in microbial strain engineering and scalable biomanufacturing solutions. It develops bio-based sustainable industrial materials, agricultural biologicals, and pharmaceutical intermediates, serving global food, agriculture, and pharmaceutical sectors.
LNAI Q2 FY2024 Key Financial Metrics
Revenue
$15.9K
Gross Profit
N/A
Operating Profit
$-4.3M
Net Profit
$-4.5M
Gross Margin
N/A
Operating Margin
-26791.8%
Net Margin
-28417.1%
YoY Growth
429.5%
EPS
$-0.07
Lunai Bioworks Inc. Q2 FY2024 Financial Summary
Lunai Bioworks Inc. reported revenue of $15.9K (up 429.5% YoY) for Q2 FY2024, with a net profit of $-4.5M (down 1.6% YoY) (-28417.1% margin).
Key Financial Metrics
| Total Revenue | $15.9K |
|---|---|
| Net Profit | $-4.5M |
| Gross Margin | N/A |
| Operating Margin | -26791.8% |
| Report Period | Q2 FY2024 |
Lunai Bioworks Inc. Quarterly Revenue & Net Profit History
Lunai Bioworks Inc. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2024 | $15.9K | +429.5% | $-4.5M | -28417.1% |
| Q1 FY2024 | $8.4K | +48.9% | $-9.2M | -109552.6% |
| Q3 FY2023 | $-142.6K | -2055.4% | $-4.3M | 3035.9% |
| Q3 FY2022 | $7.3K | +107.6% | $-6.2M | -85056.4% |
Income Statement
| Q3 2022 | Q3 2023 | Q1 2024 | Q2 2024 | |
|---|---|---|---|---|
| Revenue | $7291 | $-142571 | $8375 | $15938 |
| YoY Growth | 107.6% | -2055.4% | 48.9% | 429.5% |
Balance Sheet
| Q3 2022 | Q3 2023 | Q1 2024 | Q2 2024 | |
|---|---|---|---|---|
| Assets | $180.1M | $78.7M | $57.6M | $58.0M |
| Liabilities | $18.9M | $12.6M | $10.8M | $14.4M |
| Equity | $161.2M | $66.1M | $46.7M | $43.6M |
Cash Flow
| Q3 2022 | Q3 2023 | Q1 2024 | Q2 2024 | |
|---|---|---|---|---|
| Operating CF | $-2.8M | $-3.3M | $-2.8M | $-3.1M |